Home › Compare › MTEM vs CL

MTEM vs CL: Dividend Comparison 2026

MTEM yields 2000000.06% · CL yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MTEM wins by $4.8792278646347776e+39M in total portfolio value
10 years
MTEM
MTEM
● Live price
2000000.06%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.8792278646347776e+39M
Annual income
$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00
Full MTEM calculator →
CL
CL
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full CL calculator →

Portfolio growth — MTEM vs CL

📍 MTEM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMTEMCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MTEM + CL cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
MTEM pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MTEM
Annual income on $10K today (after 15% tax)
$170,000,005.10/yr
After 10yr DRIP, annual income (after tax)
$4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, MTEM beats the other by $4,146,935,802,432,179,400,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MTEM + CL for your $10,000?

MTEM: 50%CL: 50%
100% CL50/50100% MTEM
Portfolio after 10yr
$2.4396139323173888e+39M
Annual income
$2,439,374,001,430,694,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

MTEM
Analyst Ratings
6
Buy
1
Hold
1
Sell
Consensus: Buy
Altman Z
-24.9
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+84.9% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MTEM buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMTEMCL
Forward yield2000000.06% ✓4.00%
Annual dividend / share$2.00$2.00
Payout ratio50%50%
1-year div growth0%5% ✓
5-year div CAGR0%5% ✓
Portfolio after 10y$4.8792278646347776e+39M$28.0K ✓
Annual income after 10y$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00 ✓$899.19
Total dividends collected$4.8791964691115763e+39M$6.4K ✓
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: MTEM vs CL ($10,000, DRIP)

YearMTEM PortfolioMTEM Income/yrCL PortfolioCL Income/yrGap
1← crossover$200,010,706$200,000,006.00$11,120$420.00+$200.00M → MTEM
2$3,738,731,992,770$3,738,517,981,314.42$12,357$458.31+$3738731.98M → MTEM
3$65,315,068,744,949,500$65,311,068,301,717,240.00$13,721$499.76+$65315068744.94M → MTEM
4$1,066,400,958,023,135,400,000$1,066,331,070,899,578,300,000.00$15,227$544.58+$1066400958023135.38M → MTEM
5$16,272,185,237,131,282,000,000,000$16,271,044,188,106,197,000,000,000.00$16,885$593.02+$16272185237131282432.00M → MTEM
6$232,054,281,880,765,440,000,000,000,000$232,036,870,642,561,700,000,000,000,000.00$18,713$645.34+$2.3205428188076545e+23M → MTEM
7$3,092,799,715,549,616,000,000,000,000,000,000$3,092,551,417,468,003,600,000,000,000,000,000.00$20,724$701.81+$3.0927997155496157e+27M → MTEM
8$38,524,114,942,504,994,000,000,000,000,000,000,000$38,520,805,646,809,356,000,000,000,000,000,000,000.00$22,938$762.73+$3.8524114942504996e+31M → MTEM
9$448,468,947,092,778,960,000,000,000,000,000,000,000,000$448,427,726,289,790,500,000,000,000,000,000,000,000,000.00$25,372$828.41+$4.4846894709277894e+35M → MTEM
10$4,879,227,864,634,777,500,000,000,000,000,000,000,000,000,000$4,878,748,002,861,388,000,000,000,000,000,000,000,000,000,000.00$28,047$899.19+$4.8792278646347776e+39M → MTEM

MTEM vs CL: Complete Analysis 2026

MTEM — Stock

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

Full MTEM Calculator →

CL — Consumer Staples

CL is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in CL shares.

Full CL Calculator →
📬

Get this MTEM vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MTEM vs SCHDMTEM vs JEPIMTEM vs OMTEM vs KOMTEM vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.